Skip to main content

Table 2 Proportions of patients with cardiovascular events before initiation of treatment and during follow-up and the rates (per 1000 person years) along with 95% confidence intervals of cardiovascular events, by treatment groups

From: The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study

  

Insulin

EBID

EBID + Insulin

  

Previous

Current

Previous

Current

Previous

Current

HF

N (%)

901 (3.16)

2094 (7.33)

48 (1.71)

49 (1.75)

191 (2.43)

195 (2.48)

 

Rate (CI)

-

17.87 (17.00, 18.78)

-

4.38 (3.17, 6.05)

-

6.13 (5.30, 7.07)

MI

N (%)

286 (1.00)

312 (1.09)

22 (0.78)

14 (0.50)

73 (0.93)

39 (0.50)

 

Rate (CI)

-

2.54 (2.23, 2.89)

-

1.06 (0.55, 2.03)

-

1.15 (0.82, 1.60)

Stroke

N (%)

351 (1.23)

803 (2.81)

14 (0.50)

26 (0.93)

82 (1.04)

62 (0.79)

 

Rate (CI)

-

6.12 (5.62, 6.65)

-

2.35 (1.52, 3.64)

-

1.84 (1.41, 2.39)

MI or Stroke

N (%)

620 (2.17)

1087 (3.81)

36 (1.28)

40 (1.43)

150 (1.91)

99 (1.26)

 

Rate (CI)

 

8.50 (7.92, 9.13)

 

3.42 (2.38, 3.60)

 

2.93 (2.38, 3.60)

  1. Previous: Event prior to the index date, Current: Event after the index date.